TimesSquare Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

TimesSquare Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-764,800	Closed	-$61M	–	202
2022 Q2	$61M	Buy	764,800 +73,400	+11%	+$6.95M	0.85%	30
2022 Q1	$72.7M	Buy	691,400 +207,500	+43%	+$20.2M	0.82%	33
2021 Q4	$52.1M	Buy	483,900 +113,800	+31%	+$12.4M	0.46%	94
2021 Q3	$40.5M	Buy	+370,100	New	+$38.4M	0.35%	127
2016 Q4	–	Sell	-2,408,475	Closed	-$43.7M	–	256
2016 Q3	$43.7M	Sell	2,408,475 -1,450,815	-38%	-$28.3M	0.28%	137
2016 Q2	$63.6M	Sell	3,859,290 -206,810	-5%	-$3.35M	0.42%	96
2016 Q1	$67.4M	Buy	4,066,100 +130,800	+3%	+$2.29M	0.44%	89
2015 Q4	$85.3M	Buy	3,935,300 +456,300	+13%	+$8.88M	0.54%	65
2015 Q3	$69M	Buy	3,479,000 +695,760	+25%	+$22M	0.43%	83
2015 Q2	$96.7M	Buy	2,783,240 +667,740	+32%	+$20.4M	0.53%	63
2015 Q1	$54.9M	Sell	2,115,500 -468,500	-18%	-$8.59M	0.3%	129
2014 Q4	$33.3M	Buy	2,584,000 +409,460	+19%	+$5.13M	0.19%	176
2014 Q3	$26.7M	Buy	2,174,540 +56,500	+3%	+$657K	0.15%	196
2014 Q2	$33.5M	Buy	2,118,040 +535,240	+34%	+$7.64M	0.18%	178
2014 Q1	$23.9M	Buy	+1,582,800	New	+$17.9M	0.13%	202

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TimesSquare Capital Management's HZNP Position: Q3 2022 in Review

TimesSquare Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 764,800 shares — an estimated $61M sold.

TimesSquare Capital Management first reported a position in HZNP in Q1 2014 and held it in 15 quarters. The position peaked at $96.7M in Q2 2015. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

TimesSquare Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
TimesSquare Capital Management sold 764,800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $61M.
TimesSquare Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 15 quarters.
TimesSquare Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $96.7M in Q2 2015.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on TimesSquare Capital Management's 13F filing for Q3 2022, filed 9 Nov 2022.